INT285813

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 2.03
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERCC1) nucleoplasm (ERCC1) chromosome organization (ERCC1)
nucleolus (ERCC1) nucleus (ERCC1) cytoplasm (ERCC1)
ERCC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 2 84.52 Quite High
Pain 25 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
withdrawal 1 5.00 Very Low Very Low Very Low
Angina 1 5.00 Very Low Very Low Very Low
abdominal pain 1 5.00 Very Low Very Low Very Low
Bioavailability 1 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Antiemetics 1 5.00 Very Low Very Low Very Low
Glutamate 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypersensitivity 12 97.36 Very High Very High Very High
Apoptosis 1 96.88 Very High Very High Very High
Death 4 96.44 Very High Very High Very High
Cancer 80 96.00 Very High Very High Very High
Targeted Disruption 36 90.12 High High
Solid Tumor 4 83.20 Quite High
Shock 36 78.88 Quite High
Syndrome 17 67.36 Quite High
Toxicity 29 62.52 Quite High
Rectal Cancer 6 52.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We found that both XRCC3 and ERCC1 siRNA depletion individually decreased clonogenic survival to cisplatin, in agreement with the sensitivity of the hamster cells defective in HR and ERCC1 (Figure 1).
Negative_regulation (defective) of ERCC1
1) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0.17 Pain Relevance 0
We also find no additional sensitivity to cisplatin by siRNA co-depletion of XRCC3 and ERCC1, showing that the two proteins act on the same pathway to promote survival.



Negative_regulation (depletion) of ERCC1
2) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Abstract Doc Link PMC2770670 Disease Relevance 0.07 Pain Relevance 0
Furthermore, we found no additive effect of depleting XRCC3 in already ERCC1 siRNA-depleted cells, strongly suggesting that the two proteins act through the same pathway to promote survival in these cells.
Negative_regulation (depleted) of ERCC1
3) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0.16 Pain Relevance 0
Here, we report that ERCC1-defective cells are proficient in forming RAD51 foci after cisplatin or mitomycin C treatments.
Negative_regulation (defective) of ERCC1
4) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0 Pain Relevance 0
Furthermore, we report that RAD51 foci are induced by cisplatin or mitomycin C independently of ERCC1, but that mitomycin C-induced HR measured in a reporter construct is impaired in ERCC1-defective cells.
Negative_regulation (defective) of ERCC1
5) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Abstract Doc Link PMC2770670 Disease Relevance 0.08 Pain Relevance 0
Similarly, it has been shown that ERCC1-defective cells are hypersensitive to cross-linkers (34) and that ERCC1 may play a role in ICL repair separate to that of its function in NER (16).
Negative_regulation (defective) of ERCC1
6) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0.10 Pain Relevance 0
However, this is entirely explained by loss of viability in XRCC3 and ERCC1 siRNA-double-depleted cells and not a result of decreased sensitivity to cisplatin.
Negative_regulation (depleted) of ERCC1
7) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0.14 Pain Relevance 0
We found a slight increased survival to cisplatin in the XRCC3- and ERCC1-double-depleted cells.
Negative_regulation (depleted) of ERCC1
8) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0.15 Pain Relevance 0
(A) irs1SF and UV4DR7 cells, defective in XRCC3 and ERCC1, respectively, were treated with mitomycin C (MMC) for 4 h and DSBs then analysed by pulsed-field gel electrophoresis.
Negative_regulation (defective) of ERCC1
9) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0 Pain Relevance 0
We found that both XRCC3 and ERCC1 siRNA depletion individually decreased clonogenic survival to cisplatin, in agreement with the sensitivity of the hamster cells defective in HR and ERCC1 (Figure 1).
Negative_regulation (depletion) of ERCC1
10) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0.18 Pain Relevance 0
Interestingly, siRNA depletion of ERCC1 showed a more severe effect on clonogenic survival after exposure to cisplatin as compared to siRNA depletion of XRCC3, in agreement with survival studies comparing ERCC1-defective hamster cells with the HR-defective RAD51D-deficient cells (Figure 1B).
Negative_regulation (depletion) of ERCC1
11) Confidence 0.30 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0.13 Pain Relevance 0
(A) irs1SF and UV4DR7 cells, defective in XRCC3 and ERCC1, respectively, were treated with mitomycin C (MMC) for 4 h and DSBs then analysed by pulsed-field gel electrophoresis.
Negative_regulation (defective) of UV4DR7
12) Confidence 0.26 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2770670 Disease Relevance 0 Pain Relevance 0
capecitabine inhibits ERCC-1, a DNA repair protein that blocks the cytotoxic activity of radiation and oxaliplatin.
Negative_regulation (inhibits) of ERCC-1
13) Confidence 0.16 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886333 Disease Relevance 0.84 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox